Pamela P. Palmer, MD, PhD; examines how AcelRx’s system can deliver the benefits of PCA in terms of patient pain relief and satisfaction while reducing both drug and device safety risks as well as the overall complexity of pain management, thus reducing both drug and device safety risks as well as the overall complexity of pain management, thus reducing the cost burden on the healthcare system.
EXECUTIVE INTERVIEW – Agere: Solubilization: Accessing Broader Chemistries by Integrating Fundamental Science With Automation for Greater Predictability
Drug Development Executive: Marshall Crew, President & CEO of Agere, discusses how the company is taking a different approach that leverages expertise, but relies heavily on the principles of physical chemistry to enable automation.
Frost & Sullivan Analyst Ruplekha Choudhurie reviews some BA approaches that are being developed by a number of companies that can mitigate the biological, physical, and chemical barriers for effective delivery of poorly soluble and permeable drugs.
William Stern, PhD; Nozer Mehta, PhD; and Stephen Carl, PhD; review a highly developed, clinically proven platform technology that enables the oral delivery of peptides, overcoming the hurdles inherent to oral peptide delivery.
Degenhard Marx, PhD, and Georges Bouille provide an overview and discussion of the benefits of using intranasal saline, and a range of different devices on the market allowing administration into the nose.
James Fenton says that while the challenges presented by manufacturing pain management products can be significant for some manufacturers, for the right manufacturer, pain management products can present an ideal opportunity.
Alan Shortall indicates that following a period of relative industry stability defined by peripheral innovation, a converging series of external and internal forces are set to reshape the prefilled syringe industry so that it will better serve the emerging needs of pharmaceutical companies, patients, and other stakeholders across the continuum of care.
PLATFORM TECHNOLOGY – Tumor-Targeting Platform Delivers the Next Generation of Pediatric Cancer Drugs
Contributor Cindy H. Dubin examines the desperate need for therapies that can address underserved populations, eradicate the cancer state without severe complications, and prolong the lifespan of the patient after diagnosis, and how NanoSmart Pharmaceuticals, with its unique tumor-targeting platform, has taken on that challenge.
DRUG DELIVERY – HEPtune: A Process of Conjugating a Naturally Occurring Sugar Molecule, Heparosan, to a Drug for Enhanced Drug Delivery
Paul L. DeAngelis, PhD, shows how heparosan is a stealthy molecule well suited for use as a drug delivery vehicle due to its natural origin and properties in the body. Therefore, heparosan-modified therapeutics may offer improved pharmacokinetics, drug performance properties, as well as new options for treatment and hope for patients.
Robert Becker, PhD, Chief Research Officer at Aptalis Pharma, discusses Patient Centric Drug Delivery and the company’s role in supporting patient compliance and driving commercial value through new drug formulations.
EXCLUSIVE ONLINE CONTENT
Evonik & Stanford University Sign Research Collaboration: Evonik to Market & Develop New Drug Delivery Platform for mRNA & Gene Therapy
Evonik is working with Stanford University on a technology to deliver mRNA to tissues and organs that goes beyond the capabilities of lipid nanoparticles (LNPs)…..
In direct response to the rapid growth of the recently launched Human Factors + (HF+) program, Noble, an Aptar Pharma company, recently announced the….
EXECUTIVE INTERVIEW – Poseida Therapeutics: Creating the Next Wave of Cell & Gene Therapies With the Capacity to Cure
Eric M. Ostertag, MD, PhD, Chief Executive Officer of Poseida Therapeutics, discusses the company’s innovative approach to develop safer, more effective, accessible and affordable cell and gene therapies for patients.
The encapsulation of drugs within purposely formulated liposome nanoparticles offers the potential for more controlled and sustained release, as well as reducing toxicity and….
Stevanato Group & Corning Incorporated Sign Licensing Agreement to Offer Corning Valor Glass Vials in Presterilized SG EZ-fill Packaging Configuration
Stevanato Group recently announced a licensing agreement with Corning Incorporated to offer a combined solution that will provide biopharmaceutical companies with improved levels of….